INCY 241220 70.00P (INCY241220P70000) Stock Options, News & Quotes

US OptionsDetailed Quotes

INCY241220P70000

Watchlist

1.20
-1.00-45.45%

15min DelayClose Nov 27 16:00 ET

1.50High1.20Low

Intraday

5D
Daily

News

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
Yahoo Finance11:31 ET
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
TipRanksNov 27 20:47 ET · Ratings
Wednesday Ends With Index Decline | Wall Street Today
Kevin TraversNov 27 16:08 ET
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Kevin TraversNov 27 09:57 ET
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Kevin TraversNov 26 16:12 ET
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
BusinesswireNov 26 16:10 ET

Comments

韭菜变主力

Nov 19 12:59

$Merck & Co (MRK.US)$ $Incyte (INCY.US)$ is a great company. Buying it would be a good decision, unless Merck massively overpays.

The Thinker

Oct 29 19:14

Tech Stocks Surge While Dow Falters as U.S. Markets Prepare for Key Data

Click Here: TYNKR LAB™
U.S. stock markets closed with mixed results, reflecting cautious investor sentiment as major tech earnings approached alongside key economic data. $Dow Jones Industrial Average (.DJI.US)$ fell by 0.36%, while $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ posted gains of 0.16% and 0.81%, respectively. This divergence highlights sector-specific movements and investor positioning ahead ...

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...

Trytosaveabit

Aug 14 16:41

News

$Syndax Pharmaceuticals (SNDX.US)$ $Incyte (INCY.US)$ Reuters
5 mins ago
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (Axatilimab-Csfr) for the Treatment of Chronic Graft-Versus-Host Disease (Gvhd)